Utah has one of the nation's lowest rates of prescriptions for anti-obesity GLP-1 drugs like Wegovy and Ozempic — but their usage is rising. The intrigue: After a flush of celebrity endorsements early on,

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.